Home/Filings/4/0001062993-22-008344
4//SEC Filing

CARTER BRUCE L A 4

Accession 0001062993-22-008344

CIK 0001177648other

Filed

Mar 21, 8:00 PM ET

Accepted

Mar 22, 5:52 PM ET

Size

13.5 KB

Accession

0001062993-22-008344

Insider Transaction Report

Form 4
Period: 2022-03-21
Transactions
  • Exercise/Conversion

    Common Stock

    2022-03-21$25.58/sh+6,000$153,4806,000 total
  • Sale

    Common Stock

    2022-03-21$66.70/sh2,676$178,4893,324 total
  • Sale

    Common Stock

    2022-03-21$67.23/sh307$20,6403,017 total
  • Sale

    Common Stock

    2022-03-21$68.66/sh2,210$151,739807 total
  • Sale

    Common Stock

    2022-03-21$69.52/sh807$56,1030 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-03-216,0000 total
    Exercise: $25.58Exp: 2026-02-11Common Stock (6,000 underlying)
Footnotes (6)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021.
  • [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $66.28 to $66.99, inclusive.
  • [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $67.005 to $67.47, inclusive.
  • [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $68.509 to $68.76, inclusive.
  • [F5]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $69.39 to $70.07, inclusive.
  • [F6]100% of the shares subject to the option are fully vested and exercisable.

Issuer

ENANTA PHARMACEUTICALS INC

CIK 0001177648

Entity typeother

Related Parties

1
  • filerCIK 0001225503

Filing Metadata

Form type
4
Filed
Mar 21, 8:00 PM ET
Accepted
Mar 22, 5:52 PM ET
Size
13.5 KB